Most patients seeking abortion care or management of pregnancy loss in the second trimester will lactate, which can be physically and emotionally painful. The efficacy of a one-time dose of cabergoline has been previously demonstrated to prevent breast symptoms for these patients. This study seeks to determine if investigators can more precisely manage these patients with a reduced dose appropriate for the physiology of the second trimester, thereby reducing the medication cost and reducing or eliminating the uncomfortable medication side effects.
Protocol Amendment History
2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-03-27; most recent amendment 2026-07-15.
Status change: Not Yet Recruiting → Withdrawn2026-07-15